Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Aggressive Clinical Course of Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT) Harboring GREB1::SS18 Fusion Gene: A Case Report.

Created on 09 Oct 2026

Authors

Haruki Kasama, Ayumi Ito, Daichi Maeda, Aki Kido, Takashi Iizuka, Kaoru Abiko

Published in

The journal of obstetrics and gynaecology research. Volume 52. Issue 10. Pages e70522.

Abstract

We report a fatal case of malignant uterine tumor resembling ovarian sex cord tumor (UTROSCT) harboring the GREB1::SS18 fusion gene. A 64-year-old woman presented with a uterine tumor extending into the inferior vena cava, along with multiple hepatic and bone metastases. Although imaging suggested low-grade endometrial stromal sarcoma, histopathology revealed sex cord-like structures. GREB1::SS18 fusion was identified by RNA sequencing and independently confirmed by RT-PCR and Sanger sequencing. Despite multimodal therapy, the patient died 26 months postoperatively. While most UTROSCTs follow a benign course, rare malignant cases exist. Literature review suggests GREB1-rearranged UTROSCTs are more aggressive, occurring in older patients with larger tumors compared to ESR1-rearranged tumors. This is the first report of a fatal outcome associated with the GREB1::SS18 fusion. This case underscores the importance of molecular diagnosis for predicting malignant potential in UTROSCT, especially when atypical aggressive features are present.

PMID:
42850055
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement